Search

Your search keyword '"Cascio, Maria G."' showing total 14 results
Start Over Author "Cascio, Maria G."
14 results on '"Cascio, Maria G."'

2. Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2

Author

Raphael-Mizrahi, Bitya, primary, Attar-Namdar, Malka, additional, Chourasia, Mukesh, additional, Cascio, Maria G, additional, Shurki, Avital, additional, Tam, Joseph, additional, Neuman, Moshe, additional, Rimmerman, Neta, additional, Vogel, Zvi, additional, Shteyer, Arie, additional, Pertwee, Roger G, additional, Zimmer, Andreas, additional, Kogan, Natalya M, additional, Bab, Itai, additional, and Gabet, Yankel, additional

Published
2022
Full Text
View/download PDF

3. Author response: Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2

Author

Raphael-Mizrahi, Bitya, primary, Attar-Namdar, Malka, additional, Chourasia, Mukesh, additional, Cascio, Maria G, additional, Shurki, Avital, additional, Tam, Joseph, additional, Neuman, Moshe, additional, Rimmerman, Neta, additional, Vogel, Zvi, additional, Shteyer, Arie, additional, Pertwee, Roger G, additional, Zimmer, Andreas, additional, Kogan, Natalya M, additional, Bab, Itai, additional, and Gabet, Yankel, additional

Published
2022
Full Text
View/download PDF

8. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor

Author

Laprairie, Robert B., primary, Kulkarni, Pushkar M., additional, Deschamps, Jeffrey R., additional, Kelly, Melanie E. M., additional, Janero, David R., additional, Cascio, Maria G., additional, Stevenson, Lesley A., additional, Pertwee, Roger G., additional, Kenakin, Terrence P., additional, Denovan-Wright, Eileen M., additional, and Thakur, Ganesh A., additional

Published
2017
Full Text
View/download PDF

9. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)

Author

Kulkarni, Pushkar M., primary, Kulkarni, Abhijit R., additional, Korde, Anisha, additional, Tichkule, Ritesh B., additional, Laprairie, Robert B., additional, Denovan-Wright, Eileen M., additional, Zhou, Han, additional, Janero, David R., additional, Zvonok, Nikolai, additional, Makriyannis, Alexandros, additional, Cascio, Maria G., additional, Pertwee, Roger G., additional, and Thakur, Ganesh A., additional

Published
2015
Full Text
View/download PDF

13. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.

Author

Bolognini, Daniele, Costa, Barbara, Maione, Sabatino, Comelli, Francesca, Marini, Pietro, Di Marzo, Vincenzo, Parolaro, Daniela, Ross, Ruth A, Gauson, Lisa A, Cascio, Maria G, and Pertwee, Roger G

Subjects
CANNABINOIDS, CANNABIS (Genus), INFLAMMATION, DRUG receptors, BIOLOGICAL membranes, PERTUSSIS toxin, LABORATORY mice, PAIN, ANIMAL models in research
Abstract

Background and Purpose: The phytocannabinoid, Delta(9)-tetrahydrocannabivarin (THCV), can block cannabinoid CB(1) receptors. This investigation explored its ability to activate CB(2) receptors, there being evidence that combined CB(2) activation/CB(1) blockade would ameliorate certain disorders.Experimental Approach: We tested the ability of THCV to activate CB(2) receptors by determining whether: (i) it inhibited forskolin-stimulated cyclic AMP production by Chinese hamster ovary (CHO) cells transfected with human CB(2) (hCB(2)) receptors; (ii) it stimulated [(35)S]GTPgammaS binding to hCB(2) CHO cell and mouse spleen membranes; (iii) it attenuated signs of inflammation/hyperalgesia induced in mouse hind paws by intraplantar injection of carrageenan or formalin; and (iv) any such anti-inflammatory or anti-hyperalgesic effects were blocked by a CB(1) or CB(2) receptor antagonist.Key Results: THCV inhibited cyclic AMP production by hCB(2) CHO cells (EC(50)= 38 nM), but not by hCB(1) or untransfected CHO cells or by hCB(2) CHO cells pre-incubated with pertussis toxin (100 ng.mL(-1)) and stimulated [(35)S]GTPgammaS binding to hCB(2) CHO and mouse spleen membranes. THCV (0.3 or 1 mg.kg(-1) i.p.) decreased carrageenan-induced oedema in a manner that seemed to be CB(2) receptor-mediated and suppressed carrageenan-induced hyperalgesia. THCV (i.p.) also decreased pain behaviour in phase 2 of the formalin test at 1 mg.kg(-1), and in both phases of this test at 5 mg.kg(-1); these effects of THCV appeared to be CB(1) and CB(2) receptor mediated.Conclusions and Implications: THCV can activate CB(2) receptors in vitro and decrease signs of inflammation and inflammatory pain in mice partly via CB(1) and/or CB(2) receptor activation. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

14. Endocannabinoid Metabolic Pathways and Enzymes

Author

Ligresti, Alessia, Cascio, Maria G., and Marzo, Vincenzo D.

Abstract

Endocannabinoids, defined in 1995 as endogenous agonists of cannabinoid receptors, their anabolic and catabolic pathways, and the enzymes involved in these pathways (the "endocannabinoid enzymes"), are the subject of this review. A general strategy seems to apply to the regulation of the levels of the two major endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG). Five endocannabinoid enzymes have been cloned to date: two are responsible for the biosynthesis and degradation of anandamide, the NAPE-selective phospholipase D and the fatty acid amide hydrolase, respectively; the other three catalyse the biosynthesis and degradation of 2-AG, the sn-1-selective diacylglycerol lipases α and β and the monoacylglycerol lipase, respectively. The major features of these five proteins, their relative weight in determining endocannabinoid levels, and the possible targeting of some of them for therapeutic purpose, as well as the possibility of the existence of alternative anabolic and catabolic pathways are discussed.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results